RI 273

Drug Profile

RI 273

Alternative Names: mAb 2256; RI-273

Latest Information Update: 26 Apr 2005

Price : $50

At a glance

  • Originator Rinat Neuroscience
  • Class Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Pain

Most Recent Events

  • 26 Apr 2005 Discontinued - Preclinical for Pain in USA (unspecified route)
  • 26 Apr 2005 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (unspecified route)
  • 21 Aug 2003 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top